Lymphocyte-Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab.

Tomomitsu Matono; TOSHIFUMI TADA; Atsushi Hiraoka; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Takashi Nishimura; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Tanaka; Hidenori Toyoda; Chikara Ogawa; Takeshi Hatanaka; Satoru Kakizaki; Kazuhito Kawata; Atsushi Naganuma; Hisashi Kosaka; Hidekatsu Kuroda; Yutaka Yata; Hiroki Nishikawa; Michitaka Imai; Tomoko Aoki; Hironori Ochi; Hideyuki Tamai; Shohei Komatsu; Takanori Matsuura; Yoshihide Ueda; S KIM; Hideko Ohama; Fujimasa Tada; Satoaki Nakamura; Yoichi Nakamura; Osamu Yoshida; Kazuhiro Nouso; Asahiro Morishita; Taeang Arai; Tomomi Okubo; Taeang Arai; Akemi Tsutsui; Takuya Nagano; Hiroshi Abe; Kazunari Tanaka; Yuichi Koshiyama; Yuki Kanayama; Hidenao Noritake; Hiroko Iijima; Kosuke Matsui; Masaki Kaibori; Jumpei Okamura; Takumi Fukumoto; Y. Hiasa; Masatoshi Kudo; Takashi Kumada

doi:10.1111/liv.70570

April 1, 2026

Lymphocyte-Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab.

View Full Paper

Ask AI

Bookmark

Share

Key Points

The research aims to determine the effectiveness of the lymphocyte-monocyte ratio as a prognostic marker for survival in HCC patients receiving specific treatments.
Analyzed the relationship between lymphocyte-monocyte ratio and patient survival outcomes.
Measured progression-free survival (PFS) and overall survival (OS).
Focused on patients with unresectable hepatocellular carcinoma (HCC) receiving Durvalumab plus Tremelimumab.
Higher lymphocyte-monocyte ratios correlated with better progression-free survival (PFS).
Improved overall survival (OS) was associated with favorable lymphocyte-monocyte ratio levels.
This biomarker may aid in risk stratification for HCC patients in clinical settings.

Implication

Observational study examines lymphocyte-monocyte ratio as a survival predictor in HCC, suggesting practical clinical use.

Abstract

LMR is a readily accessible prognostic biomarker for both PFS and OS in patients with unresectable HCC treated with Dur/Tre, and may serve as a practical tool for risk stratification in clinical practice.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Matono et al. (2026) studied this question.

synapsesocial.com/papers/69a3d811ec16d51705d2ea42 https://doi.org/10.1111/liv.70570

View Full Paper

Ask AI

Bookmark

Share

Lymphocyte-Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab.

Key Points

Implication

Abstract

Discussion

Cite This Study

Lymphocyte-Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab.

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading